Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Abstract

We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10⁹/L) during their treatment-course. The majority of the patients experienced marked clinical improvement. Serious side effects were only recorded in a single patient. It is concluded that JAK-inhibition with ruxolitinib is manageable in patients with low platelet counts and should be considered in symptomatic patients who otherwise might not be candidates for treatment.

Keywords::

• Bleeding
• JAK2V617F
• myelofibrosis
• ruxolitinib
• thrombocytopenia

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informaheathcare.com/lal.

Supplementary material available online

Supplementary Figures 1–12 to be found online http://www.tandfonline.com/doi/suppl/10.3109/10428194.2015.1046867